65 / 366
Method:
Women were advised to have a colposcopy after the baseline
results and to undergo a 12-month follow-up according to EU guidelines.
Cytology was performed with ThinPrep® and mRNA of hrHPV was
detected by APTIMA® (AHPV).
Results:
There were 195 (65,2 %) AHPV-positive/cytology-negative
women with initial colposcopy and biopsy. From those, 189 had adequate
biopsies, yielding cervical disease in 48,7 % (92) of cases, including 30
cases (15,9 %) of CIN2+ lesions. Follow-up at 12
–
24 months revealed 4
additional cases of high-grade preneoplastic lesions in cases with a pre-
vious negative biopsy and 2 CIN2+ biopsies in women with a previous
CIN1 biopsy, including one adenocarcinoma in situ (AIS). Only 3 of
these women had cytological abnormalities in the follow-up and 44,4 %
were younger than 35 years
Conclusion:
The risk of harbouring a CIN2+ cervical lesión in AHPV-
positive women without cytological abnormalities raises to 15,9 % at
baseline colposcopy and increases up to 19 % with adequate follow-up.
Due to the elevated risk of high-grade lesions in young women, HPV
testing seems advisable before the age of 35
Poster Sessions
PS-01-001
HER2, chromosome 17 polysomy and DNA ploidy status in breast
cancer; a preclinical and clinical study
A. Halilovic
*
, D. Verweij, A. Simons, I. Otte-Höller, J. van der Laak, C.
van de Water, J. Dijkstra, P. van Cleef, I. Nagtegaal, P. Span, P. Bult
*
Radboud university medical center, Nijmegen, The Netherlands
Objective:
Human epidermal growth factor receptor-2 (HER2, located on
chromosome 17) amplification assessment is widely used for guiding sys-
temic treatment approaches in both primary and metastatic breast cancer. In
general, a double probe fluorescence in situ hybridisation (FISH) test is
used, whereby also loss and gain of the centromere of chromosome 17 can
be observed. This can be interpreted as monosomy or polysomy of chro-
mosome 17, respectively. With this present study we wanted to explore the
presence of polysomy of chromosome 17 and its impact on HER2 testing.
Method:
A double probe HER2 FISH test was performed on metaphase
spreads and agarcyto blocks of ten human cancer cell lines. In addition,
HER2 immunohistochemistry, DNA ploidy status assessment and a mul-
tiplex ligation-dependent probe amplification (MLPA) test was performed
on all 10 cell lines. Furthermore, dual probe HER2 FISH and DNA ploidy
status assessment was performed on a selection of 97 breast cancer cases.
Results:
Copy number gain of chromosome 17 was observed in meta-
phase spreads in eight of ten cancer cell lines, accompanied by DNA
aneuploid gains in seven. There was no polysomy of chromosome 17 in
any of the cancer cell lines. Patients
’
breast cancer samples showing
≥
3
CEP17 signals using dual probe FISH, strongly correlated with aneuploid
gains of the tumour (91.1 %;
p
< 0.001).
Conclusion:
This study has shown that copy number gain of CEP17,
which is encountered regularly in HER2 testing of breast cancer, is not
due to gain of only chromosome 17, but is a result of DNA aneuploidy of
the tumour with gain of several chromosomes. As aneuploidy is associ-
ated with poor clinical outcome, also within grade 1 and grade 2 tumours,
this might be used for therapeutic decision-making in the future.
PS-01-002
Role of core needle biopsy in diagnosis and management of papillary
lesions of breast
R. Sharma
*
, R. Goel, L. Lipi, I. Mohapatra, D. Gautam, S. Kakkar, K.
Kaur, R. Agarwal, J. Arora
*
Gurgaon, India
Objective:
The present study was aimed to compare the diagnosis of
papillary lesions of the breast on core needle biopsy (CNB), with their
subsequent excision biopsies. These findings were used to identify a
subset of patients with papillary lesions in which surveillance rather than
excision could be considered.
Method:
Retrospective analytical
–
descriptive study done from
June 2011 to February 2017.
Results:
: During this period we received 1329 breast CNBs of which 131
were diagnosed as papillary lesions. In 81 of these cases excision was
performed. On CNB, the papillary lesions were categorized as intraductal
papilloma (
n
= 47, 58 %), atypical papillary lesions (APL) based on
atypical morphology and ambiguous immunohistochemistry (IHC)
(
n
= 5, 06 %) and papillary carcinoma based on atypical morphology
and confirmatory IHC (
n
= 29, 36 %) . On follow up excision biopsy,
the positive predictive value (PPV) was 13 % for intraductal papilloma,
80 and 100 % respectively for APL and papillary carcinoma.
Conclusion:
APL or papillary carcinoma on CNB mandates excision while
the benign papillomas can be managed conservatively based on multidisci-
plinary review and individual institution
’
s upgrade rate. It is one of the largest
study on papillary lesions done in Indian population as per our knowledge.
PS-01-003
The role of core needle biopsy in diagnosis of metaplastic carcinoma
of breast in the developing countries
R. Sharma
*
, R. Goel, L. Lipi, I. Mohapatra, D. Gautam, S. Kakkar, K.
Kaur, R. Agarwal, J. Arora
*
Gurgaon, India
Objective:
To emphasie the importance of core needle biopsy (CNB) in
diagnosis of metaplastic carcinoma of breast.
Method:
Retrospective descriptive study done from January 2013
–
March 2017.
Results:
During this period we received 2309 cases of breast carcinoma,
of which 09 were metaplastic carcinoma (0.4 %) with a median age of
53 years. These cases were 07 cases of spindle cell carcinoma and 02
cases of squamous cell carcinoma. All these cases were diagnosed on core
biopsy using immunohistochemical markers; CK (AE1 + AE3),
HMWCK, CK5/6, p63, ER, PR and Hercept. 02 of such spindle cell
carcinoma were associated with DCIS. In 07 out of 09 cases, radiology
was suggestive of phyllodes tumour with multiple lobulated masses.
Conclusion:
Core needle biopsy is an important technique which can be
used to start early patient therapy in metaplastic breast carcinoma. CNB
with immunohistochemistry differentiates spindle cell tumours from meta-
plastic carcinomas whch differs in treatment and prognosis of the patients.
PS-01-004
Clinicopathological features of microinvasive breast cancer
D. Montezuma
*
, A. Pires-Luís, A. Silva, C. Castro, F. Castro, J. Abreu, C.
Leal
*
IPO - Porto, Pathology, Portugal
Objective:
Microinvasive breast cancer (MIBC) is defined as invasive
carcinoma
≤
1 mm. It is usually diagnosed in association with ductal carci-
noma in situ (DCIS). We aim to evaluate the clinicopathologic features of
MIBC and the incidence of sentinel lymph node (SLN) metastasis.
Method:
All cases of MIBC diagnosed between 2008 and 2015 were
retrieved. Clinicopathological data was analyzed. Descriptive statistics,
Chi-square, Fisher and Mann-Whitney tests, Kaplan-Meier curves and
log-rank test were performed.
Sunday, 3 September 2017, 09:30
–
10:30, Hall 3
PS-01 Breast Pathology
Virchows Arch
(
2017
)
471
(
Suppl 1
):
S1
–
S352
S51